Molecular Partners (MOLN.SW) Stock Price
Molecular Partners Price
Revenue at Molecular Partners has contracted by 15.7% per year over the past 11 years to 4.97 M CHF. For Molecular Partners, the net margin of -1,087.4% is down versus -671.7% a few years ago. The consensus 12-month price target for Molecular Partners is 8.16 CHF, about 155.8% above where the stock trades today. Of 10 analysts, 8 rate the stock a buy — an overall Buy consensus.
Molecular Partners stock price
Molecular Partners business model & stock analysis
Frequently asked questions about Molecular Partners
The business model of Molecular Partners AG revolves around its innovative biotechnology platform, DARPin®. This platform enables the development of differentiated therapeutic candidates, leveraging the targeted nature and multi-specificity of DARPins®. By pioneering the development of DARPins®, Molecular Partners AG aims to address unmet medical needs and create value for patients, physicians, and partners. Through collaborations, licensing agreements, and partnerships, the company seeks to advance its drug candidates across various therapeutic areas, including oncology, ophthalmology, and immunology. Molecular Partners AG's business model focuses on harnessing the potential of DARPins® to deliver effective and precise treatment options for patients worldwide.
Molecular Partners AG is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Molecular Partners AG in the market are large biopharmaceutical companies such as Roche Holding AG, Novartis AG, and Pfizer Inc. These companies also focus on developing innovative biologic therapies and have a broader range of resources and expertise. However, Molecular Partners AG distinguishes itself by its novel DARPin technology, which provides advantages in terms of specificity, safety, and ease of manufacturing. This unique technology sets Molecular Partners AG apart from its competitors and positions it as a leading player in the biopharmaceutical industry.
Molecular Partners AG is a Swiss biotechnology company specializing in the development of innovative therapeutic proteins known as DARPin®s. It was established in 2004 by Christian Zahnd, Michael Stumpp, and Andreas Plückthun. Molecular Partners has a strong scientific foundation in protein engineering and has collaborated with leading pharmaceutical companies globally. The company's DARPin® platform offers advantages over conventional therapeutic approaches, including high specificity, low immunogenicity, and extended half-life. Molecular Partners has a diverse pipeline targeting multiple diseases, including oncology, ophthalmology, and infectious diseases. With a commitment to advancing patient care, Molecular Partners AG continues to leverage its expertise in protein engineering to develop innovative therapies that address unmet medical needs.
Molecular Partners AG has achieved several significant milestones in its journey. The company has successfully advanced its proprietary DARPin platform, leading to strategic partnerships with renowned pharmaceutical companies. With a focus on developing innovative therapeutics, Molecular Partners has witnessed notable achievements, including the initiation of clinical trials for its lead oncology asset, MP0250. The company has also made progress in its ophthalmology pipeline, with the start of clinical studies for its candidate, abicipar. Additionally, Molecular Partners has gained global recognition through collaborations with key industry players, establishing a solid foundation for its continued growth and success.
Molecular Partners AG, a leading biotechnology company, is primarily present in several countries and regions worldwide. The company has a prominent presence in Switzerland, as it is based in Zurich. Additionally, Molecular Partners AG has established a strong foothold in Europe, including the European Union member states. Its global presence extends to the United States, with activities and collaborations in the biotech hub of Boston. With an expanding network and growing collaborations, Molecular Partners AG is well-positioned to serve and operate in various countries and regions, enabling it to contribute to the advancement of innovative biopharmaceutical solutions.
Molecular Partners AG represents a strong focus on innovation, collaboration, and scientific excellence. The company is dedicated to the development of innovative therapies based on its proprietary DARPin platform. With a commitment to addressing unmet medical needs, Molecular Partners AG strives to partner with leading pharmaceutical companies and advance the discovery and development of novel treatments. The company's corporate philosophy emphasizes a patient-centric approach, aiming to improve the lives of individuals by delivering transformative therapies. By harnessing the power of protein engineering, Molecular Partners AG aims to create breakthrough medicines and make a positive impact on healthcare.
Analysts currently set an average price target of 9.52 CHF for the Molecular Partners stock (median: 8.16 CHF), implying +198.4 % versus the latest price. The consensus is based on 10 analyst ratings.
10 analysts currently rate the Molecular Partners stock: 8 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Molecular Partners to generate revenue of 11.00 M CHF and earnings per share of -1.26 CHF.
Converted at the current exchange rate, the Molecular Partners share trades at 3.43 EUR (3.19 CHF).
The Molecular Partners share (MOLN.SW) is listed on 6 stock exchanges, including: London (0QXX.L), SIX (Zürich) (MOLN.SW), Frankfurt (6ML.F), München (6ML.MU).
Molecular Partners AG is a biotech company specializing in the development of therapeutics with multi-specificity. The company was founded in 2004 and is headquartered in Zurich, Switzerland. The business model of Molecular Partners is based on the development of innovative therapeutics based on the DARPin technology (Designed Ankyrin Repeat Proteins). These are artificially produced proteins that specifically bind to certain target structures in tumor cells or inflammation sites. By using multi-specificity, Molecular Partners' therapeutics are able to address multiple targets simultaneously, leading to improved efficacy and safety. Molecular Partners' portfolio currently includes several drug candidates in various stages of development. The main candidate is MP0250, a multi-specific antibody conjugate (SMAC) for the treatment of solid tumors. MP0250 is currently in Phase II clinical trials and has the potential to become a new standard therapy in oncology. Another important candidate is MP0274, a multi-specific antibody conjugate for the treatment of neovascular eye diseases such as wet AMD. Preliminary results indicate that MP0274 has better efficacy and longer duration of action than the current standard of treatment. In addition, Molecular Partners has partnerships with various pharmaceutical companies, including Amgen, Novartis, and Allergan, to develop innovative therapeutics together. Molecular Partners also collaborates with the biotech company AGC Biologics to improve its production technologies and bring its drug candidates to the market faster and more efficiently. Furthermore, the company also offers services in the field of protein design. It provides its customers with the opportunity to create and produce custom proteins based on the DARPin technology. These services are tailored to the biotech and pharmaceutical sectors and have the potential to generate significant scientific advances and product pipeline developments in national and international customer programs. Molecular Partners' business model is focused on close collaboration with its customers, partners, and stakeholders. The company relies on a stringent, science-based, and agile development strategy aimed at identifying and validating promising drug candidates. In this way, Molecular Partners aims to maintain and expand a strong position in the biotech market in the long term. In summary, Molecular Partners AG is an innovative biopharmaceutical company that has a strong focus on the development of multi-specific antibody conjugates (SMAC). The company relies on a stringent, science-based, and agile development strategy to bring its drug candidates to the market quickly and efficiently. Through collaboration with partners and customers in the national and international arena, as well as the provision of custom proteins, the company aims to sustainably strengthen its position in the biotech industry.
The expected revenue of Molecular Partners is 11.00 M CHF. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Molecular Partners is -47.31 M CHF. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Molecular Partners is currently -2.52. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Molecular Partners stock.
The price-to-sales ratio (P/S) of Molecular Partners is currently 10.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Molecular Partners stock.
The Eulerpool Quality Score for Molecular Partners is 1/10.
The ISIN of Molecular Partners is CH0256379097. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Molecular Partners is A12DEH. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Molecular Partners is MOLN.SW. The ticker symbol is used to trade Molecular Partners shares on the stock exchange.
Molecular Partners stock
Molecular Partners Peer Group
Molecular Partners Ticker
Molecular Partners FIGI
All fundamentals and in-depth analysis of Molecular Partners
Our stock analysis for Molecular Partners stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Molecular Partners. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.